Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Mukherjee, Asok K.; Gupta, Gaurav; Bhattacharjee, Surajit; Guha, Subhasish Kamal; Majumder, Saikat; Adhikari, Anupam; Bhattachrya, Parna; Majumdar, S.; Majumdar, Subrata

doi:10.1016/j.jinf.2010.05.003

Cited by 19 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells were cultured in RPMI-1640 medium supplemented with 10% FCS, 2 mM glutamine, 100 U of penicillin/ml, and 100 mg of streptomycin/ml. THP1 cells in the log phase of growth were differentiated by incubation for 2 days in medium containing 20 ng/ml of phorbol myristate acetate (PMA) (Sigma, USA) [25].…”

Section: Methodsmentioning

confidence: 99%

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9

Mukherjee

Gupta

Adhikari

et al. 2012

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9

Mukherjee

Gupta

Adhikari

et al. 2012

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

“…Of interest, in vitro studies with THP1 cells (human acute monocytic leukemia cell line) showed that L-AMB could mediate effective parasite clearance due to strong induction of free radicals and proinflammatory cytokines [18]. Moreover, other studies showed that the process of parasite apoptosis is important for successful survival of Leishmania spp.…”

Section: Discussionmentioning

confidence: 99%

Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B

2012

View full text Add to dashboard Cite

AbstractWe retrospectively evaluated the rate of renal dysfunction during treatment with liposomal amphotericin B (L-AmB) (3–4 mg/kg, for 7–10 days) in nine consecutive patients with visceral leishmaniasis (VL). During the first week of treatment, 5 patients (56%) experienced transient deterioration of renal function, with a rise in serum creatinine to 1.27–2.44 times the baseline level, and a parallel elevation of uric acid levels without other metabolic or electrolyte disturbances. Serum renal function parameters were restored to normal levels after the completion of therapy, on day 21. These 5 patients had presented with prolonged fever and/or significant spleen enlargement, reflecting high parasite load. This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, especially in patients with high parasite load.

show abstract

“…would present resistance to AmB did not identify resistant strains (Wayne, 2002;Negri et al, 2010;Mukherjee et al, 2010). Negri et al (2010), observed that AmB showed the lowest MIC against C. albicans among all the tested drugs (fluconazole, itraconazole, voriconazole and AmB).…”

Section: Resistancementioning

confidence: 99%

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Voncik¹,

Fermino²,

Cardoso³

et al. 2016

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Despite advances in the research on new antifungal agents, Amphotericin B (AmB) is still considered as the antifungal of choice for treating most systemic mycoses due to its potency and broad-spectrum action. However, this drug has limited use because of its toxic effects on kidneys, liver and blood. The search for new and safe formulations of AmB is essential because of the emergence of antifungal resistance to other drugs and the increased number of immunosuppressed patients. Nanoparticles are a promising alternative towards achieving lower toxicity and improved pharmacokinetic properties. This study is a literature review of the use of AmB and the toxicity of formulations. Some of the current new formulations show some advantageous characteristics as compared to AmB. However, there is still need for a continued search for an effectively improved formulation.

show abstract

Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Cited by 19 publications

References 57 publications

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9

Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B

Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

Contact Info

Product

Resources

About